Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.60 |
| ▸ | NPY4R | P50391 | 8/20 | 0.60 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.60 |
| ▸ | NPY1R | P25929 | 6/20 | 0.60 |
| ▸ | CALCR | P30988 | 4/20 | 0.58 |
| ▸ | F2 | P00734 | 2/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.55 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.54 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.54 |
| ▸ | TFPI | P10646 | 1/20 | 0.54 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30262137 | 0.89 | NTSR1 (0.58) | CALCRF2NTSR1NTSR2 | |
| SCHEMBL30262121 | 0.88 | CALCR (0.59) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30335722 | 0.87 | TFPI (0.64) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL31000921 | 0.86 | NPY2R (0.63) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30607381 | 0.86 | NPY2R (0.68) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL31012331 | 0.85 | MAPK8 (0.64) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30906476 | 0.85 | NPY2R (0.71) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30495668 | 0.85 | CALCR (0.74) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30648485 | 0.84 | CALCR (0.66) | CALCRF2HCRTR1HCRTR2 | |
| SCHEMBL29479810 | 0.84 | NPY2R (0.62) | NPY2RNPY4RNPY5RNPY1RCALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376151-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376151-A1 | STAPLED PEPTIDES AND METHODS THEREOF | VIP, IAPP, GLP1R | NPY2R 128/4885NPY4R 167/4885NPY5R 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.